000 | 03109cam a2200409 i 4500 | ||
---|---|---|---|
001 | 200454468 | ||
999 |
_c200454468 _d72680 |
||
003 | TR-AnTOB | ||
005 | 20241115144700.0 | ||
006 | m o d | ||
007 | cr cn aaaau | ||
008 | 201124s2021 nju ob 001 0 eng | ||
020 |
_a9781119612698 _q(hardback) |
||
020 |
_z9781119612742 _q(e-book) |
||
020 |
_z9781119612735 _q(epub) |
||
040 |
_aDNLM/DLC _beng _erda _cDLC _dTR-AnTOB |
||
041 | 0 | _aeng | |
060 | 0 | 0 |
_aWH 380 _bB655 2021 |
096 |
_aWH380 _bB655 2021 EBK |
||
245 | 0 | 0 |
_aBlood and marrow transplantation long term management : _bsurvivorship after transplant / _cedited by Bipin N Savani, André Tichelli. |
250 | _aSecond edition | ||
264 | 1 |
_aNew Jersey : _bWiley-Blackwell, _c2021. |
|
300 | _a1 online resource. | ||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
504 | _aBIBINDX | ||
520 |
_a"Hematopoietic cell transplantation (HCT) provides curative therapy for a variety of diseases. Over the past several decades, significant advances have been made in the field of HCT and now HCT has become an integral part of treatment modality for a variety of hematologic malignancies and some nonmalignant diseases. HCT remains an important treatment option for a wide variety of hematologic and nonhematologic disorders, despite recent advances in the field of immunologic therapies. Factors driving this growth include expanded disease indications, greater donor options (expanding unrelated donor registries and haploidentical HCT), and accommodation of older and less fit recipients. The development of less toxic pretransplant conditioning regimens, more effective prophylaxis of graft-versus-host disease (GVHD), improved infection control, and other advances in transplant technology have resulted in a rapidly growing number of transplant recipients surviving long-term free of the disease for which they were transplanted. The changes over decades in the transplant recipient population and in the practice of HCT will have almost inevitably altered the composition of the long-term survivor population over time. Apart from an increasingly older transplant recipient cohort, the pattern of transplant indications has shifted from the 1990s when chronic myeloid leukemia made up a significant proportion of allo-HCT indications. Changes in cell source, donor types, conditioning regimens, GVHD prophylaxis, and supportive care have all occurred, with ongoing reductions in both relapse and non-relapse mortality (NRM) have been demonstrated"-- _cProvided by publisher. |
||
650 | 2 |
_aHematopoietic Stem Cell Transplantation _9143632 |
|
650 | 2 |
_aLong Term Adverse Effects _xprevention & control _9143633 |
|
650 | 2 |
_aDisease-Free Survival _9143636 |
|
655 | 0 |
_aElectronic books _2local _92032 |
|
700 | 1 |
_aSavani, Bipin N. _eeditor _9143641 |
|
700 | 1 |
_aTichelli, André _eeditor _9143645 |
|
856 | 4 | 0 |
_uhttps://onlinelibrary.wiley.com/doi/book/10.1002/9781119612780 _zOnline access link to the resource |
942 |
_2NLM _cEBK |